Announcing the financial results for the third quarter ended 30 September 2021, BioCryst Pharmaceuticals, Inc. President and CEO Jon Stonehouse says:
“With the significant revenue we expect to generate with Orladeyo – our oral, once-daily treatment for prevention of HAE attacks – in its first year of launch, BioCryst plans to repeat our clinical and commercial success with Orladeyo again and again as we bring much-needed oral medicines to patients waiting for them.”
Regarding the U.S. launch of Orladeyo Charlie Gayer, Chief Commercial Officer of BioCryst, says:
“Almost a year into the launch of Orladeyo, we continue to see strong, consistent demand from new patients switching to Orladeyo from their existing injectable prophylactic and acute therapies, and it is exciting to see the positive impact Orladeyo is having on their lives. With the excellent start to the launch, and the excitement we hear from physicians and patients, Orladeyo is now on a trajectory to become the market leader in HAE prophylaxis.”
The number of new physicians prescribing Orladeyo grew by another 25 percent in the third quarter and the Orladeyo prescriber base has now increased to include nearly half of the top 500 HAE-treating physicians in the United States. Orladeyo has been very well received by payors and is now covered by nearly all national and regional pharmacy benefit managers.
(Source: BioCryst)
